Results 171 to 180 of about 31,798 (219)

Initial Vancomycin Taper for the Prevention of Recurrent Clostridioides difficile Infection: A Randomized Clinical Trial.

JAMA Netw Open
McDonald EG, Butler-Laporte G, Brophy JM, Elsayed S, Frenette C, Huseen I, Loo VG, Moran K, Coburn B, Hota SS, Longtin Y, Kong LY, Muller MP, Steiner TS, Valiquette L, Daneman N, Daley P, Nott C, MacFadden DR, Kandel CE, Chen Y, Perez-Patrigeon S, Lee TC, TAPER-V Team.   +23 more
europepmc   +1 more source

Relationship Between <i>Clostridioides difficile</i> Stool Concentration, Nucleic Acid Amplification Test Results, and Environmental Contamination. [PDF]

Open Forum Infect Dis
Lee MM, Reske KA, Hink T, Fishbein SRS, Newcomer EP, Cass C, Olsen MA, Dantas G, Burnham CD, Dubberke ER.   +9 more
europepmc   +1 more source

Microbiome Therapeutics for Clostridioides difficile Infection. [PDF]

Infect Dis Clin North Am
Lucky CW, Medernach RL, Kelly BJ, Kwon JH, Woodworth MH.   +4 more
europepmc   +1 more source

Attenuation of <i>Clostridioides difficile</i> Infection by <i>Clostridium hylemonae</i>. [PDF]

J Microbiol Biotechnol
Choi S, Kwon H, Kim WK, Ko G.
europepmc   +1 more source

Diagnostic challenges and treatment approaches for <i>Clostridioides difficile</i> infection in IBD patients. [PDF]

Front Microbiol
Ali A, AlHussaini KI.
europepmc   +1 more source

Screening and targeted prophylaxis for Clostridioides difficile infection. [PDF]

Clin Microbiol Infect
Ziegler MJ, Anesi J, Tolomeo P, Glaser L, Cowden L, Cressman L, Huang E, Patel A, Lautenbach E, Pegues DA, Kelly BJ.   +10 more
europepmc   +1 more source